Eli Lilly’s Obesity Pill Receives FDA Approval

(SeaPRwire) –   Individuals seeking GLP-1 medications for weight management now have an additional choice. On April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), a novel daily pill developed by Eli Lilly for the treatment of obesity. This medication is sanctioned for use by individuals who are overweight or obese and present with at least one co-existing weight-related health condition, such as elevated blood pressure or cardiac or renal problems.

Novo Nordisk’s Wegovy pill, approved by the FDA in December 2025, was the initial oral GLP-1 drug to receive regulatory clearance. Foundayo now stands as the second. Earlier iterations of GLP-1s were self-administered injectable drugs, typically taken weekly.

The FDA’s approval of Foundayo was predicated on two trials conducted by Lilly involving overweight or obese participants. These studies demonstrated that individuals receiving the drug experienced an average weight reduction of 11% of their body weight, or 25 pounds, over a period exceeding one year, in contrast to placebo recipients who lost an average of 5.3 pounds. In comparison, the Wegovy pill, which the FDA approved in December 2025, facilitates a loss of 16% to 17% of initial body weight compared to those on placebo. These two oral medications target distinct GLP-1 hormones implicated in weight regulation.

Mechanism of Foundayo

Similar to the injectable versions of GLP-1s, Foundayo is offered in six dosage strengths, spanning from 0.8mg to 17.2mg. Patients, in collaboration with their physicians, commence with the lowest dose and progressively escalate to higher doses; not all individuals may require the maximum dose.

Foundayo targets a distinct GLP-1 compared to those found in Lilly’s injectable formulations (Mounjaro and Zepbound), according to Dr. Dan Skovronsky, the company’s chief scientific and product officer. Lilly acquired the license for orforglipron from a Japanese pharmaceutical firm in 2018. While Lilly was then prioritizing the advancement of tirzepatide, which subsequently became Mounjaro for diabetes and Zepbound for weight loss, it simultaneously pursued the development of orforglipron as an oral medication.

Individuals using orforglipron are not required to limit food or beverage intake after ingesting the pill, Skovronsky states. (The Wegovy pill is a peptide, necessitating a 30-minute fasting period after administration.) Orforglipron, being a small molecule, is rapidly absorbed by the body, entering the bloodstream to reach target tissues, Skovronsky clarifies.

He notes that the adverse effects observed with Foundayo mirror those associated with injectable GLP-1 medications—such as nausea, constipation, vomiting, diarrhea, and indigestion, alongside the less common elevated risk of thyroid cancer.

The Potential of an Oral Medication

“We perceive Foundayo as a foundational GLP-1 therapy,” stated Eli Lilly CEO David Ricks during a press briefing, elucidating the drug’s nomenclature. Lilly’s research indicates that Foundayo could serve as an effective maintenance therapy for individuals aiming to sustain weight loss after utilizing injectable GLP-1s to achieve a target weight. Ricks further mentioned the company’s “broad ambitions” to pursue additional indications for the drug, including sleep apnea, hypertension, and stress urinary incontinence, with planned submissions to the FDA in the coming months and years.

An oral daily medication could enhance the accessibility of GLP-1 drugs. Studies reveal that approximately half of current users of the injectable form discontinue treatment, either temporarily or permanently. For some, the significant cost presents a barrier; for others, it is the stigma and inconvenience associated with injections. Given that pills are less expensive to manufacture than injectable medications, both Lilly and Novo Nordisk have reached an agreement with the White House to introduce the initial doses of their oral drugs at $149 per month for uninsured individuals and Medicare beneficiaries with diabetes. Later this summer, a broader cohort of Medicare beneficiaries will qualify for coverage under a new initiative, encompassing those with other obesity-related health conditions such as hypertension or kidney or heart disease, with their monthly cost set at $50. Prices will escalate with increasing doses, and Ricks indicated that these costs would be capped at $299 per month for participants in the company’s Self-Pay Journey program who renew their prescriptions within 45 days of the previous one. For those not enrolled in the program, the highest dose would cost $349 per month.

For individuals with insurance coverage, Ricks affirmed that the drug would cost no more than $25 per prescription, provided they download a savings card from the company’s website.

Foundayo marks the first drug approved under the FDA’s new Commissioner’s National Priority Voucher program, designed to accelerate the review of novel medications. Its approval was granted merely 100 days after Lilly submitted its request, a review Ricks described as “thorough and deep with no differences other than time scale.” Under the conventional review system, the FDA would have had until January 2027 to render a decision.

This swift action means Foundayo will be available next week via Lilly Direct and in pharmacies. “Obesity is a problem of immense scale, affecting 100 million people in the U.S. and up to 1 billion globally,” states Skovronsky. “This is a population health challenge that demands a population health solution. We aim to positively impact human health, and we have the opportunity to achieve that with this pill.”